The clinical and preclinical research to be presented includes the
application of Tumor Treating Fields in seven cancer types
ST. HELIER, Jersey--(BUSINESS WIRE)--
Novocure (NASDAQ: NVCR) announced today 35 presentations on Tumor
Treating Fields at the American Association for Cancer Research (AACR)
Annual Meeting 2018, April 14 through April 18, in Chicago. Tumor
Treating Fields is a cancer therapy that uses electric fields tuned to
specific frequencies to disrupt cell division, inhibiting tumor growth
and causing affected cancer cells to die.
The volume of Tumor Treating Fields presentations marks a record number
of abstracts for Novocure at this conference. Of the 35 presentations,
18 are externally led research. The clinical and preclinical research to
be presented includes the application of Tumor Treating Fields in seven
cancer types, representing Novocure’s evolving pipeline and commitment
to developing Tumor Treating Fields for a variety of solid tumors.
“Over the past several years, the volume of presentations on Tumor
Treating Fields at the AACR Annual Meeting has increased substantially,
demonstrating what we believe to be an increased interest in Tumor
Treating Fields from the scientific community,” said Dr. Eilon Kirson,
Novocure’s Chief Science Officer and Head of Research and Development.
“Tumor Treating Fields shows promise in multiple solid tumor types, and
we are honored to have the opportunity to share our growing volume of
research at a leading conference in cancer research.”
Poster presentations
(Abstract CT086) Safety of TTFields and radiotherapy (RT) for newly
diagnosed glioblastoma: Interim safety results from a pilot study. R.
Grossman. 1 to 5 p.m. CDT Monday, April 16. (Poster section 42, poster
board #7)
(Abstract #CT081) Tumor treating fields in combination with Bevacizumab
in recurrent or progressive meningioma in a phase 2 study. P. Kumthekar.
1 to 5 p.m. CDT Monday, April 16. (Poster section 42, poster board #2)
(Abstract #CT082) TTFields concurrent with standard of care for the
treatment of stage 4 non-small cell lung cancer (NSCLC) following
platinum failure: Phase 3 LUNAR study. U. Weinberg. 1 to 5 p.m. CDT
Monday, April 16. (Poster section 42, poster board #3)
(Abstract #CT084) HEPANOVA: A phase 2 trial of tumor treating fields
concomitant with sorafenib for advanced hepatocellular carcinoma. A.
Grosu. 1 to 5 p.m. CDT Monday, April 16. (Poster section 42, poster
board #5)
(Abstract #CT105) Safety of TTFields applied to the torso: A
meta-analysis of 176 patients from four phase I-II trials. I. Vergote. 1
to 5 p.m. CDT Monday, April 16. (Poster section 42, poster board #26)
(Abstract #CT108) Tumor Treating Fields (TTFields) in combination with
Lomustine (CCNU) in the EF-14 phase 3 clinical study - A safety
analysis. A. Kinzel. 1 to 5 p.m. CDT Monday, April 16. (Poster section
42, poster board #29)
(Abstract #CT092) Effect of Tumor treating fields in children with
recurrent or progressive high-grade glioma and ependymoma; Pediatric
Brain Tumor Consortium PBTC048. S. Goldman. 1 to 5 p.m. CDT Monday,
April 16. (Poster section 42, poster board #13)
(Abstract #CT100) Effects of Tumor Treating Fields (TTFields) on
health-related quality of life (HRQoL) in newly diagnosed glioblastoma:
An exploratory analysis of the EF-14 randomized phase III trial. T.
Walbert. 1 to 5 p.m. CDT Monday, April 16. (Poster section 42, poster
board #21)
(Abstract #CT157) PANOVA-3: A phase 3 study of TTFields with
nab-paclitaxel and gemcitabine for front-line treatment of
locally-advanced pancreatic adenocarcinoma (LAPC). U. Weinberg. 1 to 5
p.m. CDT Tuesday, April 17. (Poster section 42, poster board #9)
(Abstract #CT138) Open-label personalized targeted intervention to
maximize TTFields intensity in recurrent GBM (OptimalTTF Trial). N.
Mikic. 8 a.m. to 12 p.m. CDT Tuesday, April 17. (Poster section 42,
poster board #21)
(Abstract #LB-257) Incremental cost-effectiveness ratio of tumor
treating fields for newly diagnosed glioblastoma. G. Guzauskas. 1 to 5
p.m. CDT Tuesday, April 17. (Poster section 35, poster board #14)
(Abstract #CT151) TTFields and radiosurgery for 1 to 10 brain metastases
from NSCLC in the phase III METIS study. M. Mehta. 1 to 5 p.m. CDT
Tuesday, April 17. (Poster section 42, poster board #3)
(Abstract # CT097) Quantitative MR measurements in glioblastoma
patients: mean diffusivity with Tumor Treating Fields plus standard
therapy versus standard treatment alone. J. Vymazal. 1 to 5 p.m. CDT
Monday, April 16. (Poster section 42, poster board #18)
(Abstract #676) Preliminary investigation into the dosimetric impact of
tumor treating field arrays on concurrent radiotherapy for
newly-diagnosed glioblastoma. G. Stachelek. 1 to 5 p.m. CDT Sunday,
April 15. (Poster section 30, poster board #14)
(Abstract #621) Evaluating the compatibility of Tumor Treating electric
Fields with key anti-tumoral T cell functions. G. Diamant. 1 to 5 p.m.
CDT Sunday, April 15. (Poster section 27, poster board #15)
(Abstract #1343) Induction of autophagy following TTFields application
serves as a survival mechanism mediated by AMPK activation. A.
Shteingauz. 8 a.m. to 12 p.m. CDT Monday, April 16 (Poster section 14,
poster board #21)
(Abstract #1860) Tumor-Treating-Fields (TTFields) effects on
glioblastoma cells are augmented by mitotic checkpoint inhibition. A.
Kessler. 8 a.m. to 12 p.m. CDT Monday, April 16. (Poster section 37,
poster board #18)
(Abstract #1865) The combined treatment of 150 kHz Tumor Treating Fields
(TTFields) and Sorafenib inhibit hepatocellular carcinoma in vitro. K.
Gotlib. 8 a.m. to 12 p.m. CDT Monday, April 16. (Poster section 37,
poster board #23)
(Abstract #1463) Efficacy of Tumor Treating Fields (TTFields) and aurora
B kinase inhibitor. D. Krex. 8 a.m. to 12 p.m. CDT Monday, April 16.
(Poster section 20, poster board #5)
(Abstract #1707) Tumor Treating Fields Exert Cellular and Immunologic
Effects. E. Wong. 8 a.m. to 12 p.m. CDT Monday, April 16. (Poster
section 32, poster board #2)
(Abstract #2273) Meta-analysis of cancer cell lines based on their
response to Tumor Treating Fields (TTFields). G. L. Shahaf. 1 to 5 p.m.
CDT Monday, April 16. (Poster section 12, poster board number 30)
(Abstract #2284) Semi-automated MRI segmentation workflow for
glioblastoma treated by Tumor Treating Fields. J.J. Timmons. 1 to 5 p.m.
CDT Monday, April 16. (Poster section 13, poster board #11)
(Abstract #3199) Computational studies show that Tumor Treating Fields
can be delivered to the infratentorial brain at therapeutic levels. S.
Levy. 8 a.m. to 12 p.m. CDT Tuesday, April 17. (Poster section 8, poster
board #5)
(Abstract #3195) The molecular mechanism of action and the cellular
targets of TTFields. A. Kalra. 8 a.m. to 12 p.m. CDT Tuesday, April 17.
(Poster section 8, poster board #1)
(Abstract #3204) Transducer array configuration optimization for
treatment of pancreatic cancer using Tumor Treating Fields (TTFields) A.
Naveh. 8 a.m. to 12 p.m. CDT Tuesday, April 17. (Poster section 8,
poster board #10)
(Abstract #3209) Numerical modeling of intracellular mechanisms in
tumor-treating fields. K. Carlson. 8 a.m. to 12 p.m. CDT Tuesday, April
17. (Poster section 8, poster board #15)
(Abstract #3217) Newly identified role of tumor treating fields in DNA
damage repair and replication stress pathways. N.K. Karanam. 8 a.m. to
12 p.m. CDT Tuesday, April 17. (Poster section 8, poster board #23)
(Abstract #3208) Optimal array layouts for tumor treating fields therapy
in glioblastoma - oblique array layouts are superior to standard LR and
AP positions. N. Mikic. 8 a.m. to 12 p.m. CDT Tuesday, April 17. (Poster
section 8, poster board #14)
(Abstract #4194) Tumor Treating Fields (TTFields) affect invasion
properties and cell morphology of various cancer cells in vitro. R. S.
Schneiderman. 1 to 5 p.m. CDT Tuesday, April 17. (Poster section 8,
poster board #20)
(Abstract #4398) In vitro Tumor Treating Fields (TTFields) alter
proliferation and morphology of patient-derived high-grade meningioma
cell lines. S. K. Michelhaugh. 1 to 5 p.m. CDT Tuesday, April 17.
(Poster section 18, poster board #24)
(Abstract #4376) Tumor Treating Fields (TTFields) decrease proliferation
of patient-derived lung cancer brain metastasis cells in vitro. S. K.
Michelhaugh. 1 to 5 p.m. CDT Tuesday, April 17. (Poster section 18,
poster board #2)
(Abstract #4111) Water content based Electrical Properties Tomography
(wEPT) for modelling delivery of Tumor Treating Fields to the brain. C.
Tempel-Brami. 1 to 5 p.m. CDT Tuesday, April 17. (Poster section 5,
poster board #12)
(Abstract #4637) Tumor Treating Fields (TTFields) have
anti-proliferative effects on high-grade paediatric brain tumor cell
lines. J. Branter. 1 to 5 p.m. CDT Tuesday, April 17. (Poster section
29, poster board #10)
(Abstract #5828) Withaferin A and Tumor Treating Fields synergistically
inhibit glioma proliferation. E. Chang. 8 a.m. to 12 p.m. CDT Wednesday,
April 18. (Poster section 37, poster board #24)
(Abstract #5898) A Systems Approach for Determining the Mechanism of
Resistance to Tumor Treating Fields in Glioblastoma. C. Dongjiang. 8
a.m. to 12 p.m. CDT Wednesday, April 18. (Poster section 40, poster
board #15)
About Novocure
Novocure is an oncology company developing a profoundly different cancer
treatment utilizing a proprietary therapy called Tumor Treating Fields,
the use of electric fields tuned to specific frequencies to disrupt
solid tumor cancer cell division. Novocure’s commercialized product is
approved for the treatment of adult patients with glioblastoma. Novocure
has ongoing or completed clinical trials investigating Tumor Treating
Fields in brain metastases, non-small cell lung cancer, pancreatic
cancer, ovarian cancer and mesothelioma.
Headquartered in Jersey, Novocure has U.S. operations in Portsmouth, New
Hampshire, Malvern, Pennsylvania and New York City. Additionally, the
company has offices in Germany, Switzerland, Japan and Israel. For
additional information about the company, please visit www.novocure.com
or follow us at www.twitter.com/novocure.
Forward-Looking Statements
In addition to historical facts or statements of current condition, this
press release may contain forward-looking statements. Forward-looking
statements provide Novocure’s current expectations or forecasts of
future events. These may include statements regarding anticipated
scientific progress on its research programs, development of potential
products, interpretation of clinical results, prospects for regulatory
approval, manufacturing development and capabilities, market prospects
for its products, and other statements regarding matters that are not
historical facts. You may identify some of these forward-looking
statements by the use of words in the statements such as “anticipate,”
“estimate,” “expect,” “project,” “intend,” “plan,” “believe” or other
words and terms of similar meaning. Novocure’s performance and financial
results could differ materially from those reflected in these
forward-looking statements due to general financial, economic,
regulatory and political conditions as well as more specific risks and
uncertainties facing Novocure such as those set forth in its Annual
Report on Form 10-K filed on February 22, 2018, with the U.S. Securities
and Exchange Commission. Given these risks and uncertainties, any or all
of these forward-looking statements may prove to be incorrect.
Therefore, you should not rely on any such factors or forward-looking
statements. Furthermore, Novocure does not intend to update publicly any
forward-looking statement, except as required by law. Any
forward-looking statements herein speak only as of the date hereof. The
Private Securities Litigation Reform Act of 1995 permits this discussion.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180315005391/en/
Source: Novocure